The projected market share for Ingrezza and Austedo in 2025 is influenced by various factors including patient population, treatment guidelines, and physician prescribing habits.
How do Ingrezza and Austedo treat tardive dyskinesia?
Both Ingrezza (valbenazine) and AustedO (deutetrabenazine) are approved medications for the treatment of tardive dyskinesia, a neurological disorder characterized by involuntary, repetitive movements. Ingrezza works by selectively inhibiting the vesicular monoamine transporter 2 (VMAT2), which reduces the amount of dopamine available in the brain, thereby decreasing abnormal movements [1]. AustedO also targets VMAT2, but it uses deuterium-modified tetrabenazine, which is designed for slower metabolism and potentially longer-lasting effects [2].
What is the current market situation for tardive dyskinesia treatments?
As of recent data, Ingrezza has established a significant presence in the tardive dyskinesia market. AustedO, while also approved for this indication, entered the market later and is working to gain its own share. The treatment landscape for tardive dyskinesia is evolving, with these two VMAT2 inhibitors being the primary pharmacological options.
When does Ingrezza's patent expire?
Ingrezza's composition of matter patent is expected to expire in 2029, with potential for extensions [3]. This patent expiry date is a crucial factor for future market competition, particularly from generic manufacturers.
When does AustedO's patent expire?
AustedO also has patent protection that will influence its market exclusivity. Information regarding the specific expiry dates for AustedO's relevant patents can be found through patent tracking resources [4].
Who are the manufacturers of Ingrezza and AustedO?
Ingrezza is manufactured by Neurocrine Biosciences [1]. AustedO is manufactured by Teva Pharmaceuticals [2].
What are the projected sales for Ingrezza and AustedO in the near future?
Analysts project continued sales growth for Ingrezza, driven by its established efficacy and physician familiarity. AustedO is expected to see its sales increase as it gains more traction with prescribers and potentially expands its approved indications. Projections for 2025 suggest that Ingrezza will likely maintain a leading position in market share, although AustedO is anticipated to capture a growing segment of the market [1][2]. Specific market share percentages for 2025 are subject to ongoing market dynamics and competitive pressures.
Sources:
1. DrugPatentWatch.com
2. DrugPatentWatch.com
3. DrugPatentWatch.com
4. DrugPatentWatch.com